CYCN Quote, Financials, Valuation and Earnings

iBio has a net margin of -372.68% compared to Cyclerion Therapeutics's net margin of -4444.57%. Cyclerion Therapeutics's return on equity of -51.71% beat iBio's return on equity of -148.3%.

Cyclerion Therapeutics has a consensus price target of --, signalling upside risk potential of 2407.84%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 45.16%. Given that Cyclerion Therapeutics has higher upside potential than iBio, analysts believe Cyclerion Therapeutics is more attractive than iBio.

Cyclerion Therapeutics has a beta of 1.875, which suggesting that the stock is 87.498% more volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

Cyclerion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cyclerion Therapeutics pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

Cyclerion Therapeutics quarterly revenues are $194K, which are larger than iBio quarterly revenues of $175K. Cyclerion Therapeutics's net income of -$723K is higher than iBio's net income of -$4M. Notably, Cyclerion Therapeutics's price-to-earnings ratio is 3.20x while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cyclerion Therapeutics is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -372.68% compared to Cyclerion Therapeutics's net margin of -49.65%. Cyclerion Therapeutics's return on equity of -51.71% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Cyclerion Therapeutics has a consensus price target of --, signalling upside risk potential of 2407.84%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that Cyclerion Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Cyclerion Therapeutics is more attractive than NovaBay Pharmaceuticals.

Cyclerion Therapeutics has a beta of 1.875, which suggesting that the stock is 87.498% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Cyclerion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cyclerion Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Cyclerion Therapeutics quarterly revenues are $194K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Cyclerion Therapeutics's net income of -$723K is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Cyclerion Therapeutics's price-to-earnings ratio is 3.20x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cyclerion Therapeutics is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -372.68% compared to Cyclerion Therapeutics's net margin of -2357.27%. Cyclerion Therapeutics's return on equity of -51.71% beat Palatin Technologies's return on equity of --.

Cyclerion Therapeutics has a consensus price target of --, signalling upside risk potential of 2407.84%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Cyclerion Therapeutics has higher upside potential than Palatin Technologies, analysts believe Cyclerion Therapeutics is more attractive than Palatin Technologies.

Cyclerion Therapeutics has a beta of 1.875, which suggesting that the stock is 87.498% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Cyclerion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cyclerion Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Cyclerion Therapeutics quarterly revenues are $194K, which are smaller than Palatin Technologies quarterly revenues of $350K. Cyclerion Therapeutics's net income of -$723K is higher than Palatin Technologies's net income of -$7.8M. Notably, Cyclerion Therapeutics's price-to-earnings ratio is 3.20x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cyclerion Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Protara Therapeutics has a net margin of -372.68% compared to Cyclerion Therapeutics's net margin of --. Cyclerion Therapeutics's return on equity of -51.71% beat Protara Therapeutics's return on equity of --.

Cyclerion Therapeutics has a consensus price target of --, signalling upside risk potential of 2407.84%. On the other hand Protara Therapeutics has an analysts' consensus of -- which suggests that it could grow by 391.62%. Given that Cyclerion Therapeutics has higher upside potential than Protara Therapeutics, analysts believe Cyclerion Therapeutics is more attractive than Protara Therapeutics.

Cyclerion Therapeutics has a beta of 1.875, which suggesting that the stock is 87.498% more volatile than S&P 500. In comparison Protara Therapeutics has a beta of 1.779, suggesting its more volatile than the S&P 500 by 77.897%.

Cyclerion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protara Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cyclerion Therapeutics pays -- of its earnings as a dividend. Protara Therapeutics pays out -- of its earnings as a dividend.

Cyclerion Therapeutics quarterly revenues are $194K, which are larger than Protara Therapeutics quarterly revenues of --. Cyclerion Therapeutics's net income of -$723K is higher than Protara Therapeutics's net income of -$11.2M. Notably, Cyclerion Therapeutics's price-to-earnings ratio is 3.20x while Protara Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cyclerion Therapeutics is -- versus -- for Protara Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.